|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Table S1- Characteristics of HIV+ treatment-naïve subjects | | | | |
| Chronic Infection | | | | |
|
| **PTID** | **Viral Load** | **CD4+ Count** | **YPI** | **bNAb %** |
| **10031** | 50 | 612 | 8 | 60% |
| **10066** | 50 | 1326 | 12 | 45% |
| **10071** | 50 | 881 | 16 | 5% |
| **20016** | 50 | 735 | 6 | 0% |
| **10070** | 222 | 810 | 10 | 0% |
| **10002** | 390 | 682 | 20 | 60% |
| **10055** | 402 | 599 | 5 | 25% |
| **10040** | 440 | 704 | 18 | 30% |
| **10024** | 500 | 800 | 7 | 40% |
| **10067** | 648 | 930 | 20 | 50% |
| **10060** | 722 | 688 | 4 | 25% |
| **10068** | 987 | 754 | 12 | 20% |
| **10003** | 1684 | 891 | 10 | 65% |
| **20010** | 3740 | 1124 | 8 | 10% |
| **10017** | 4007 | 418 | 6 | 25% |
| **20001** | 6002 | 562 | 3 | 55% |
| **10014** | 17159 | 881 | 3 | 60% |
| **10076** | 17693 | 832 | 5 | 15% |
| **10027** | 19410 | 547 | 13 | 20% |
| **10042** | 20211 | 331 | 21 | 100% |
| **10028** | 29345 | 800 | 13 | 40% |
| Early Infection | | | | |
|
| **PTID** | **Viral Load** | **CD4+ Count** | **YPI** | **bNAb %** |
| **20008** | 137 | 946 | 1 | 15% |
| **20015** | 147 | 574 | 1 | 0% |
| **20018** | 1886 | 1374 | 2 | 5% |
| **20023** | 2910 | 508 | 0.5 | 5% |
| **20004** | 3294 | 666 | 1 | 5% |
| **20013** | 3998 | 400 | 2 | 60% |
| **20025** | 4856 | 472 | 0.5 | 5% |
| **20005** | 6179 | 903 | 1.5 | 5% |
| **20026** | 8248 | 300 | 0.5 | 5% |
| **20020** | 18005 | 602 | 1 | 5% |
| **20049** | 18034 | 680 | 0.1 | 0% |
| **20027** | 30000 | 300 | 0.5 | 55% |
| **10006** | 38799 | 357 | 2 | 10% |
| Subjects are categorized by chronic and early infection and then arranged by increasing viral load. CD4+ counts and viral load were obtained at time of blood draw. Neutralizing antibody breadth was determined as described in methods (results shown in Fig. 4). PTID = patient identification. YPI = years post-infection. bNAb = broadly neutralizing antibody breadth. 34 subjects are listed here, but due to sample availability, not all individuals were evaluated with each *ex vivo* and *in vitro* cellular assay. | | | | |